Anti-inflammatory activity of clove (Eugenia caryophyllata) essential oil in human dermal fibroblasts.

Article Details

Citation

Copy to clipboard

Han X, Parker TL

Anti-inflammatory activity of clove (Eugenia caryophyllata) essential oil in human dermal fibroblasts.

Pharm Biol. 2017 Dec;55(1):1619-1622. doi: 10.1080/13880209.2017.1314513.

PubMed ID

28407719 [ View in PubMed

]

Abstract

CONTEXT: Clove (Eugenia caryophyllata Thunb. [Myrtaceae]) essential oil (CEO) has been shown to possess antimicrobial, antifungal, antiviral, antioxidant, anti-inflammatory and anticancer properties. However, few studies have focused on its topical use. OBJECTIVE: We investigated the biological activity of a commercially available CEO in a human skin disease model. MATERIALS AND METHODS: We evaluated the effect of CEO on 17 protein biomarkers that play critical roles in inflammation and tissue remodelling in a validated human dermal fibroblast system, which was designed to model chronic inflammation and fibrosis. Four concentrations of CEO (0.011, 0.0037, 0.0012, and 0.00041%, v/v) were studied. The effect of 0.011% CEO on genome-wide gene expression was also evaluated. RESULTS AND DISCUSSION: CEO at a concentration of 0.011% showed robust antiproliferative effects on human dermal fibroblasts. It significantly inhibited the increased production of several proinflammatory biomarkers such as vascular cell adhesion molecule-1 (VCAM-1), interferon gamma-induced protein 10 (IP-10), interferon-inducible T-cell alpha chemoattractant (I-TAC), and monokine induced by gamma interferon (MIG). CEO also significantly inhibited tissue remodelling protein molecules, namely, collagen-I, collagen-III, macrophage colony-stimulating factor (M-CSF), and tissue inhibitor of metalloproteinase 2 (TIMP-2). Furthermore, it significantly modulated global gene expression and altered signalling pathways critical for inflammation, tissue remodelling, and cancer signalling processes. CEO significantly inhibited VCAM-1 and collagen III at both protein and gene expression levels. CONCLUSIONS: This study provides important evidence of CEO-induced anti-inflammatory and tissue remodelling activity in human dermal fibroblasts. This study also supports the anticancer properties of CEO and its major active component eugenol.

DrugBank Data that Cites this Article

Drugs

Clove oil

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Clove oil	C-X-C motif chemokine 10	Protein	Humans	Unknown	Not Available	Details
Clove oil	Collagen alpha-1(I) chain	Protein	Humans	Unknown	Not Available	Details
Clove oil	Granulocyte-macrophage colony-stimulating factor receptor subunit alpha	Protein	Humans	Unknown	Not Available	Details
Clove oil	Vascular cell adhesion protein 1	Protein	Humans	Unknown	Antagonist	Details